Meta-analysis and GRADE evaluation of Guanxinning Tablets in treatment of angina pectoris of coronary heart disease.
10.19540/j.cnki.cjcmm.20221015.501
- Author:
Xiao-Ying LI
1
;
Dong-Xia SUN
1
;
Ya-Ni XU
2
;
Xiao-Han GAO
1
;
Kai-Fang FAN
3
Author Information
1. Shanxi University of Chinese Medicine Jinzhong 030619, China.
2. Zhejiang Chinese Medical University Hangzhou 310000, China.
3. Shanxi University of Chinese Medicine Jinzhong 030619, China Affiliated Hospital of Shanxi University of Chinese Medicine Taiyuan 030024, China.
- Publication Type:Journal Article
- Keywords:
GRADE;
Guanxinning Tablets;
Meta-analysis;
angina pectoris;
coronary heart disease;
effectiveness
- MeSH:
Humans;
C-Reactive Protein;
Reproducibility of Results;
Drugs, Chinese Herbal/adverse effects*;
Angina Pectoris/drug therapy*;
Coronary Disease/drug therapy*;
Tablets
- From:
China Journal of Chinese Materia Medica
2023;48(1):247-255
- CountryChina
- Language:Chinese
-
Abstract:
This study aims to evaluate the efficacy and safety of Guanxinning Tablets+conventional western medicine in the treatment of angina pectoris of coronary heart disease, and provide evidence-based references for clinical medication. Retrieved from CNKI, Wanfang, VIP, SinoMed, PubMed, EMbase, Cochrane Library, randomized controlled trial(RCT) about Guanxinning Tablets for the treatment of angina pectoris of coronary heart disease from the inception to April 2022 were collected. After literature screening and data extraction, the bias risk assessment tool recommended by the Cochrane evaluation manual handbook 5.1.0 was used to evaluate the quality of the included literature, and RevMan 5.3 and Stata 14.0 were used for Meta-analysis. Eighteen RCTs were finally included, involving 2 281 patients. Meta-analysis showed that, compared with conventional western medicine treatment alone, Guanxinning Tablets+conventional western medicine significantly improved angina pectoris efficacy(RR=1.33, 95%CI[1.13, 1.57], P=0.000 8), electrocardiogram efficacy(RR=1.32, 95%CI[1.02, 1.71], P=0.03), and exercise duration(MD=59.53, 95%CI[39.16, 79.90], P<0.000 01) and reduced the incidence of cardiovascular events(MACE)(RR=0.43, 95%CI[0.30, 0.61], P<0.000 01), high sensitivity C-reactive protein(hs-CRP)(MD=-2.75, 95%CI[-3.71,-1.79], P<0.000 01), and endothelin-1(ET-1) levels(MD=-9.34, 95%CI[-11.36,-7.32], P<0.000 01). There was no statistically significant difference in the incidence of adverse reactions between two groups(RR=0.91, 95%CI[0.68, 1.22], P=0.52). Subgroup analysis showed that Guanxinning Tablets may have better short-term efficacy(less than 6 months) in the treatment of heart-blood stasis syndrome. GRADE grading showed that angina pectoris efficacy, electrocardiogram efficacy, MACE, and ET-1 were in the medium grade, hs-CRP and adverse reactions were in the low grade, and exercise duration was in the extremely low grade. In conclusion, the efficacy of Guanxinning Tablets+conventional western medicine is better than conventional western medicine treatment alone, with good safety. Therefore, it is recommended for the short-term treatment of patients with heart-blood stasis syndrome. However, the evidence quality of some results is low, and more rigo-rous RCT is still needed to enhance the reliability of evidence.
